Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
In DMSO USD 324 In stock
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Gck expression in WT primary hepatocytes transduced with FOXO1 and KR-FOXO1 adenoviruses in the presence or absence of trichostatinA (TSA).

    Cell, 2017, 171(4):824-835.e18. Trichostatin A (TSA) purchased from Selleck.

    Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

  • (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 M3PaSGZ2dmO2aX;uJGF{e2G7 NUO2[3ZkOC55zszN NG\GNG0zPGh? MWXleIhidm:u MX\lcohidmOnczDFUoFEKGGlZYT5cIF1cW:wIHHu[EBqdmO{ZXHz[ZMhTU6jQzDhZpVv\GGwY3WgbY4hfGinIITveIFtKGOnbHygcJl{[XSnIHHu[EBifCC2aHWgZ4VtdCC|dYLmZYNm NGHRUJMzPTd6N{C3PS=>
TE13 NHXoUGhHfW6ldHnvckBCe3OjeR?= M{m3ZlAvO87:TR?= NWX3[|BwOjSq M1O3fJVxNXKnZ4XsZZRmeyCUQWPTSlVCKGyndnXs MmDyNlU2Pzl4NkW=
TE13 NEjmbW5CeG:ydH;zbZMhSXO|YYm= MWKwMlPPxE1? Ml3PNlRp NWfjZ4IycW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?= NWf0[3pmOjV3N{m2OlU>
MEFs Mm\CSpVv[3Srb36gRZN{[Xl? MYO1{txO NFXqNXoyPmh? MmDWbY5kemWjc3XzJJRp\SCHUFXDJIF1fGGlaH3lcpQtKFSrcjDk[YxqfmW{eTDhcoQhfGinIHXm[olkcWWwY4mgc4YheGWmZYP0ZYwh\m:{bXH0bY9v MVeyOVQ5OjZ|NB?=
SW480  NFXOSW5HfW6ldHnvckBCe3OjeR?= MW[wMlHPxE1? MVy0PIg> NFjocmFFVVOR NETNb2dz\X[ncoPld{BGVVR? NVXoRmY2OjV2M{S5PVc>
PC3  MkP6SpVv[3Srb36gRZN{[Xl? MWWwMlHPxE1? MkDqOFhp NEPV[phFVVOR NXrYN2NlemW4ZYLz[ZMhTU2W NUK4dIR6OjV2M{S5PVc>
SW480  NF3MSYFHfW6ldHnvckBCe3OjeR?= M3vmclAvOc7:TR?= MWC0PIg> NYXWV|JyTE2VTx?= NXe3THRO[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u M3;lcVI2PDN2OUm3
PC3  MXTGeY5kfGmxbjDBd5NigQ>? NVXP[5lIOC5zzszN NF\OT4Y1QGh? M4jV[2ROW09? MYjheJRmdnWjdHXzJIlvfmG|aX;uJIFv\CCvaXfyZZRqd25? NEHlT2UzPTR|NEm5Oy=>
SW480  MXvGeY5kfGmxbjDBd5NigQ>? NVLmdmRxOC5zzszN NUXXcXIzPDiq MnzQSG1UVw>? MVfpcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz MkPwNlU1OzR7OUe=
PC3  NI\scpdHfW6ldHnvckBCe3OjeR?= NGCwSoIxNjIQvF2= NHHk[|M1QGh? M2DzZmROW09? M1TTSYlv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ? M2DOdFI2PDN2OUm3
A431 NWn0[21OSXCxcITvd4l{KEG|c3H5 MofKNk8yOC93MD:xNFBvVQ>? MVW0PIg> MYfEUXNQ MWrpcohq[mm2czD0bIUh[2WubDDndo94fGh? NV;ofpo5OjV|N{GwOlk>
A431 M4DNVmZ2dmO2aX;uJGF{e2G7 MmLwOVBvVQ>? NHP2XpEzNzZxMUKvNlRp Mom5SG1UVw>? NWTw[Fdu[WO2aY\heIV{KHB{MTDhcoQhcW6qaXLpeJMhSVSIMzDlfJBz\XO|aX;u MnfpNlU{PzFyNkm=
MDA-MB-231 M3;T[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPzUIVqOC14MEDuUS=> MXiyOIg> NUj1SZpETE2VTx?= MlS0TWM2OCCxZjCxNFBvVQ>? NYrueZpIOjVzOUK3NlE>
MCF7 NGT0T3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHjNE03ODCwTR?= NFLrcpQzPGh? NFjmdGhFVVOR MXTJR|UxKG:oIEe1cm0> NWqyXog2OjVzOUK3NlE>
SKOV-3 NETsWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPkNU0yOM7:TR?= MXyyOIg> MY\EUXNQ MmjvTWM2OCCxZjC1MlbPxE1? M4rBTlI2OTZ7NEmx
A549 NX3wb4d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonnNU0yOM7:TR?= NIrpVXkzPGh? M4L5RmROW09? M4jySWlEPTBib3[gN{4z|ryP MlLvNlUyPjl2OUG=
SKOV-3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUKwMlEuOc7:TR?= NVu0[2lzPDiq MVrEUXNQ Mlr6TWM2OCCxZjCwMlfPxE1? M{TKSVI2OTZ7NEmx
A549 NXvRRndOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7XNnAxNjFvMd88US=> M{PMOlQ5cA>? MX;EUXNQ MY\JR|UxKG:oIECuNljPxE1? M1zzRlI2OTZ7NEmx
SKOV-3 MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXReIFkOC5yMT2wMlnPxE1? MlqxO|Jp M3rYWWROW09? M3v3NGlEPTBib3[gNE4{Os7:TR?= NWfSVGhtOjVzNkm0PVE>
A549 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;rNE4xOS1yLkpOwG0> M3rBT|czcA>? MUPEUXNQ NV;YRZNNUUN3MDDv[kAxNjB4zszN NELnSnQzPTF4OUS5NS=>
HeLa M{nwVWZ2dmO2aX;uJGF{e2G7 Mn7XNlUxdk1? NV\GN|JIOT[q NHfZNIZFVVOR MkL4bY5kemWjc3XzJGN[WDGDMTDtVm5CKGW6cILld5Nqd28EoB?= NWrrTpRxOjVzMU[2PFg>
CNE2 MmTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVKxNFAuPjBybl2= NVzVRmhEOjRxNEivO|Jp MkflbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFrUSHQzPDl4OUmwNS=>
PC3 NGDlN4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\6TW1COTByLUGwNFBvVQ>? NEDOe5ozPGh? M2\qSGlEPTBib3[gN|Axdk1? MmjaNlQ5PTR4NUi=
LNCaP NIHUcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULBRXRoOTByLUGwNFBvVQ>? MXqyOIg> MWnJR|UxKG:oIEOwNI5O M1jwNlI1QDV2NkW4
HeLa  MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7QbHZVOs7:TR?= M2[wNVQ5cA>? M{HCS4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDhZo92fCB{NTW= MU[yOFg1PjF|NR?=
HMEC-1  MUnGeY5kfGmxbjDBd5NigQ>? MWOzNFBvVQ>? MnfjNlRp MXrpcoNz\WG|ZYOg[ZhxemW|c3nvckBw\sLiVlXHSnI{yqCvUl7B MUmyOFcyODZ|MR?=
HeLa MlO1SpVv[3Srb36gRZN{[Xl? M3\KeVFuVQ>? MkjDNE42cA>? NXvWOW9u[WKxbHnzbIV{KHSqZTD0c5RidCCKRFHDJIFkfGm4aYT5 MkPMNlQ4ODd2N{S=
ACP02 M{Hvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nTVlI2OC9|NUCvOVAxdk1? MV2yOIg> M2ntVoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? NHjHR|QzPDZ4OEW0Oy=>
ACP03 NETUbY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCyOVAwOzVyL{WwNI5O NE\uZVgzPGh? MXLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlib3[gZZBxem:6aX3heIVtgSB5MNMgKUBifCB{NUFCpI5O NGH2NpEzPDZ4OEW0Oy=>
U87 GBM MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjuNVAxNzNyMD:1NFAhdk1? NHnmXYY4OiCq MYKxNFAmKGW2aHHuc4w> M{XSepJm\HWlZYOgcYVidiClZXzsJI52dWKncjDifUA{OSxiNUSsJIFv\CB3ONMgKS=> MVuyOFQ3PDh2MR?=
U87 GBM MlLtSpVv[3Srb36gRZN{[Xl? M3H0S|ExOC93MECgUo0> NIjTbVY1QCCq NV7yU25yOTByJTDleIhidm:u MlvDTY5lfWOnczDT[Y5me2OnbnPlMWxqc2ViQXz0[ZJifGmxboOgbY4hVnWlbHXhdkBOd3KyaH;sc4d6 M1PxflI1PDZ2OESx
RPE NFjke3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW1N5gxNjJxMD60M|AvQC9zIN88US=> M{fSeFI1NzR6L{eyJIg> MXjEUXNQ M2DITIlvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIJ6KGOnbHygZ5lkdGViYYLy[ZN1 MXKyOFQ2PjZyMh?=
HT29  NHf2PHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYexPFAhdk1? NXvGOIVbPzJiaB?= NIXZW4NKSzVyIH;mJFE5OCCwTR?= NXTkdXhlOjR|NkiyOlU>
hMSCs MUPGeY5kfGmxbjDBd5NigQ>? NXq0NVVbPi5{NTDuUS=> MUiyOEBp MUPEUXNQ NYLwPINxe3SjYnnsbZpmeyCKaYP0c45mKEGlZYT5cIF1cW:wIHHu[EB1cGViRYjwdoV{e2mxbjDv[kBRdHW{aYDveIVvfCCJZX7ldy=> MX6yOFMyOjN3Nh?=
Huh7  M3;nSWZ2dmO2aX;uJGF{e2G7 NFPTeXExNjFxMD61M|EvOCEQvF2= NH7CdowzPGh? Mnzid5VxeHKnc4Pld{B[XEiGQ{Kg[4Vv\SCneIDy[ZN{cW:w NUP3U4lUOjR{Nkm2O|I>
SKOV3 M4exSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rSSFAvODVvMjFOwG0> M{jPXlExNzJ2L{S4JIg> MU\EUXNQ NWe3ZlUydWWmaXH0[ZMh\3Kxd4ToJIFzemW|dDDpckBiKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NXLoVpB2OjR{MkO4NFE>
A2780 MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rZTlAvODVvMjFOwG0> M3qwXVExNzJ2L{S4JIg> NVjLXI96TE2VTx?= MVrt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M3y2SFI1OjJ|OECx
SRA01/04  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW2NE4zKM7:TR?= MUO0PEBp NYPBSWVVTE2VTx?= MXXzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> NGjk[XkzPDF3N{i3PC=>
HLEB3 M3fBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LsdFAvOiEQvF2= M{HqelQ5KGh? MkLISG1UVw>? MYHzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> MkftNlQyPTd6N{i=
SRA01/04  M3rqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYiwMlQwOC56IN88US=> M1vMblQ5KGh? MWPEUXNQ NFHFSZJqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NHrTXJkzPDF3N{i3PC=>
HLEB3 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj6NE41NzBwODFOwG0> MY[0PEBp MYTEUXNQ NWHjfZVlcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MkPaNlQyPTd6N{i=
HCT116 NX3aOll4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnYb2tEOC5{IN88US=> NHrQUpUyOiCq NIKzWFZmdmijbnPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JJJi\GmjdHnvci=> NWGwUJh1OjRzMkKyN|E>
CA46 Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUmzM|YwOTJxMkSvOFghdk1? NH;GRYY1QCCq NGPmOFNqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHH0JFI1KGGwZDC0PEBvVcLi NGfFNlQzPDB4NEm1NS=>
PMNs NXzTcJhqTnWwY4Tpc44hSXO|YYm= NIXUO5M{OCCwTR?= Mn7NOFghcA>? NIHYfnRqdmirYnn0d{Bm\m[ncn;jfZRwe2m|LDDISGFEKGGldHn2bZR6KGGwZDDSZYMh[WO2aY\peJk> NUC0R5lmOjN7OEi2NVc>
H1299 NI\LN3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L0OlHDqM7:TdMg M4n2O|I1NzR6L{eyJIg> MXLleIhidm:u NU\SRpdPcW6lcnXhd4V{KGOnbHyg[IVifGhiYX\0[ZIhOjSq NHTJS2QzOzlzNk[wPS=>
A549 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVSyRpVGOC5{NT:wMlUwOSEQvF2= NV\HTXhQOjRxNEivO|IhcA>? NX\5XHVC\XSqYX7vcC=> NWTrOm5qcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJIlvKGOxbnPlcpRz[XSrb36gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MnnPNlM5Pjd7OUG=
H1299 Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqwMlI2NzBwNT:xJO69VQ>? Mmn2NlQwPDhxN{KgbC=> NUHv[5Uy\XSqYX7vcC=> MXrpcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz NVe5NFlVOjN6Nke5PVE>
A549 NE\4dFFCeG:ydH;zbZMhSXO|YYm= NY\6SJFIOC53L{Gg{txO M{e4clQ5KGh? MVfleIhidm:u NIHONWhqdmS3Y3XzJINmdGxiYYDvdJRwe2m| Mo\VNlM5Pjd7OUG=
H1299 NGrBPFNCeG:ydH;zbZMhSXO|YYm= MUSwMlUwOSEQvF2= NHv5PJo1QCCq NXPmXGNY\XSqYX7vcC=> NVLQNIN{cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NHjX[W8zOzh4N{m5NS=>
SUM149PT M3;XWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTsVppLOi95LkWvNVAh|ryP NVvOVHZkPDhiaB?= NVfvfo9lTE2VTx?= M3rLeIlv\HWlZYOgZ4VtdCCmZXH0bEBifCB{IN88UUBqdnOnboPpeIl3\Wy7 Mn\qNlM4QTJ4M{i=
SUM190PT M{\XZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmezOVAwOTByL{K1NEBvVQ>? NYjpOWVZPDhiaB?= NX30fFVVTE2VTx?= M1TXcYlv\HWlZYOgZ4VtdCCmZXH0bEBifCB3MDDuUUB{\W6|aYTpeoVtgQ>? NV\rR2U2OjN5OUK2N|g>
HCT1 MlyzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PTR|AvOi9zLkCvOU4xKM7:TR?= MVexNk8zPC9|Nj:0PEBp NWW1N2c5cW6mdXPld{Bk\WyuIHTlZZRpKGmwIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MYSyN|c4ODByMB?=
Lovo Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2f6[|AvOi9zLkCvOU4xKM7:TR?= M{fqO|EzNzJ2L{O2M|Q5KGh? NF\xSZBqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> M1TlbVI{PzdyMECw
AGS NEHwR5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV:wMlAyPS1zIN88US=> NYHz[3hnPzJiaB?= NFjIe3BqdmS3Y3XzJINmdGxiZHXheIgh[2:wY3XueJJifGmxbjDk[ZBmdmSnboTsfS=> NX7MT5R[OjN5NEWwNlQ>
Huh7 M3zMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy2UJQyKM7:TR?= M3HD[|I1KGh? NXGycmFPTE2VTx?= MVjy[YR2[2W|IHHic5V1KDJyJTD2bYFjcWyrdIpCpC=> MXKyN|Y1Ozl|Mx?=
ECC1 NHfVRnZHfW6ldHnvckBCe3OjeR?= NIfabVY2ODBibl2= MX21JIQ> NVjGXpdzTE2VTx?= NFS3d3VqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= NV:xOnpuOjN3M{C3Olk>
HEC1A NWXNdGdxTnWwY4Tpc44hSXO|YYm= NGjo[Ho2ODBibl2= MkPTOUBl NULjfWV6TE2VTx?= NIK1OZRqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= NHfKdoMzOzV|MEe2PS=>
EN1 M2XzWWZ2dmO2aX;uJGF{e2G7 MYG1NFAhdk1? NFfvZlE2KGR? MW\EUXNQ NIrmU3pqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= MVWyN|U{ODd4OR?=
MFE296 MUjGeY5kfGmxbjDBd5NigQ>? MWO1NFAhdk1? NFfhNVU2KGR? MnTOSG1UVw>? MYnpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? MXKyN|U{ODd4OR?=
HASMCs M2e1eGZ2dmO2aX;uJGF{e2G7 MVqwMVUxOCCwTR?= NYrhZWlMPiCm MYjkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKQVTDJIFv\CClZXzsJJZq[WKrbHn0fS=> M1XmUFI{PTF6NE[3
U373 M1qzRmZ2dmO2aX;uJGF{e2G7 NHf1U44xNjJ3L{CuOU8yKM7:TR?= NWfUeWtUOjRiaB?= MVLpcoNz\WG|ZYOgVHIuSiCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEXBfoFlSw>? MorYNlM1PzRzN{G=
ARN8  NHXVR2xHfW6ldHnvckBCe3OjeR?= M3WweVAvODVvMjFOwG0> M372PVI1KGh? M3X5[JJm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDwOVMu\GWyZX7k[Y51KGenbnXzJIJ6KE63dHzpck0{ MXWyN|Q4ODV2MB?=
MCF7 M1LWemZ2dmO2aX;uJGF{e2G7 NVfQRYdWOC5yNT2yJO69VQ>? NFzYZ|YzPCCq NYKwW3p7emWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? MUWyN|Q4ODV2MB?=
H1299  NX3nd40{TnWwY4Tpc44hSXO|YYm= Mnr4NE4{O+LCk{JCpOK2VQ>? NYrGUm8zOjRxNEigbC=> MUXEUXNQ M{G1VYlv[3KnYYPld{BGNWOjZHjldolvKHC{b4TlbY4hdGW4ZXzzJIRwe2ViZHXw[Y5l\W62bIm= NHH1eFAzOzR4MUm3OS=>
H1299 NWroW2ppTnWwY4Tpc44hSXO|YYm= M2rXfVAvPSEQvF2= MmHlOFghcA>? M13sVWROW09? MVrpcohq[mm2czD0bIUhdWmpcnH0c5J6KHCxdHXueIlidCClb33ibY5mKHerdHigd4ltcWKrbnnu MUOyN|Q3OTl5NR?=
H1299 MULGeY5kfGmxbjDBd5NigQ>? NI[2WYwxNjVizszN MWe0PEBp M2r1[2ROW09? NFjLcVNqdmirYnn0d{B1cGViaX72ZZNqfmWwZYPzxsAh[2:vYnnu[UB4cXSqIIPpcIljcW6rbh?= M1PQU|I{PDZzOUe1
MG-63  NIrkOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH4OIUxNjNizszN M3n6bFEzNTl4IHi= NF7MVHBFVVOR NGP1XIRqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu Mm[5NlM1PTF6MUe=
LM8 M3XHdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\zNE4{KM7:TR?= M{\sZlEzNTl4IHi= NGHnVHZFVVOR NUjPRmQ5cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> NFfQPYUzOzR3MUixOy=>
K562 NFP2UW9HfW6ldHnvckBCe3OjeR?= MkjONE42KM7:TR?= MnTUNlQhcA>? NVrxbndt\XSqYX7vcC=> MVrk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> M2LYbVI{PDNyOUW3
HEL MnW5SpVv[3Srb36gRZN{[Xl? MUSwMlUh|ryP NYO0PW1bOjRiaB?= M36wNoV1cGGwb3y= MoG3[IVkemWjc3XzJJRp\SCnbor5cYUh[WO2aY\peJkhd2ZiSFTBR5Mh[29vdILlZZRu\W62IIfpeIgh[3W{Y4XtbY4> NEXVXHgzOzR|MEm1Oy=>
HL60 MYrBdI9xfG:|aYOgRZN{[Xl? NUDjS4ZJOSEQvF2= MmLTNlQhcA>? Moe3bY5lfWOnc9MgZ4VtdCCmZXH0bC=> MmnsNlM1ODB3MUm=
KG1 NHTPfI1CeG:ydH;zbZMhSXO|YYm= NEnQSHoyKM7:TR?= M17NS|I1KGh? M3S2[olv\HWlZYRCpINmdGxiZHXheIg> MYCyN|QxODVzOR?=
Kazumi NFfWcplCeG:ydH;zbZMhSXO|YYm= NVzoNXhEOSEQvF2= MUOyOEBp NWftbpFbcW6mdXPld:Kh[2WubDDk[YF1cA>? MXGyN|QxODVzOR?=
K562 NYnlc5JzSXCxcITvd4l{KEG|c3H5 MXSxJO69VQ>? MWmyOEBp M2fRNYlv\HWlZYRCpINmdGxiZHXheIg> NIXiXJYzOzRyMEWxPS=>
THP1 M37xZ2Fxd3C2b4Ppd{BCe3OjeR?= M3jIPVEh|ryP NG\p[WgzPCCq NX;4N2FpcW6mdXPld:Kh[2WubDDk[YF1cA>? MUKyN|QxODVzOR?=
SH-SY5Y MoTxSpVv[3Srb36gRZN{[Xl? MXSyOVAhdk1? MUKxOkBp M{[wXYNp[W6pZYOg[ZhxemW|c3nvckBx[XS2ZYLuJI9nKGenbnXzJIlvfm:udnXkJIlvKGOqb3zld5Rmem:uIIP5cpRp\XOrczygeZB1[WunIHHu[EBm\m[udYi= NYHmeos2OjN|Mk[0NlI>
HEK293 NFnLOZNHfW6ldHnvckBCe3OjeR?= NGfZbXkyKML3TdMg M33qUlE5KGkEoB?= NGTGSmxqdmirYnn0d{B1cGVia3HsbZJqdi15LX3l[IlifGWmIILlZ5J2cXSvZX70JI9nKHO7boDobYxqdi1zIHHn[5Jm\2G2ZYOgbY51dyCjZ3fy[ZNwdWW| MnjFNlMzQDR6NEi=
HTK M2\ETWZ2dmO2aX;uJGF{e2G7 NGiycZM1ODBibl2= NGTjV|g4OiCq MmPwbY5pcWKrdIOgWGdHNc7{4pETTY5lfWOnZDDNfY9ncWK{b3LsZZN1KESrZn\ldoVvfGmjdHnvci=> NGjPT|IzOzJ6NECwNi=>
HTK NXuzdlM3TnWwY4Tpc44hSXO|YYm= MnfDNVAxNThyMH7N NULCZXVpPzJiaB?= Mor3Zoxw[2u|IGTHSk3PuuLCk1nu[JVk\WRiUl;TJIFv\CCKMl:yxsBC[2O3bYXsZZRqd25? NU\NbIFWOjN{OESwNFI>
Caco-2  M13tVmZ2dmO2aX;uJGF{e2G7 NW[3NGxoOSEEtV5CpC=> MlvENlQhcA>? MnrH[IVkemWjc3XzJHNGWlRicILveIVqdiCneIDy[ZN{cW:w NVizSGFvOjNzOUWwO|A>
HeLa NVj6UGdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\YdlExOCCwTR?= NFLSUFAzPCCq MmDPSG1UVw>? MV\JR|UxKG:oIEGwNI5O NEHjXFczOzF4NUe0PC=>
HeLa NEi2R4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm0UXI6PDBibl2= NUPxNVA2PDhiaB?= M3jrZ2ROW09? NInYZ3lKSzVyIH;mJFQxdk1? MkiwNlMyPjV5NEi=
HeLa MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjkb|gzOCCwTR?= M2PrWVczKGh? MX;EUXNQ NVP4NYNIUUN3MDDv[kAzOG6P M17qXFI{OTZ3N{S4
HeLa MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPJV|kyOC9|MD:1NEBvVQ>? M4DkWVczKGh? M{S2eWROW09? MlH1bY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiTV3QJEjPnM7qbTmgcI9{eyClZXzsd{Bld3OnIHTldIVv\GWwdHz5 NFX5OoUzOzF4NUe0PC=>
MDA-MB-231 NW\FPVl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml:2NlUuPDByIH7N Mn2zOFghcA>? MmLHTWM2OCCxZjCyOlMvOm6PwrC= NFTidXYzOzB3NUG5PC=>
MCF-7  MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{frNFI2NTRyMDDuUS=> MnjvOFghcA>? NGrTRmJKSzVyIH;mJFIzOC52bl2= NHL3RnEzOzB3NUG5PC=>
ECC-1  NWrCZ4lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHucnhkOTByIH7N Mo[3NlQhcA>? M1zpPIV1cGGwb3y= MXLpcoNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZZBweHSxdHnjJI52[2ynaTD0c{A{PSV? MUSyN|AzQDhyMx?=
HEC-1A NY[3NVJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4WyVFExOCCwTR?= Ml7sNlQhcA>? NELITVVmfGijbn;s MV\pcoNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZZBweHSxdHnjJI52[2ynaTD0c{A{QSV? NFTSe3UzOzB{OEiwNy=>
NHAC-kn MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuxNE8yODBxNUCwJI5O M2DW[|EzKGh? Mn7GSG1UVw>? M4HON2lEPTBib3[gOVAxdk1? NH3IW2szOzBzN{i3NS=>
A549 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fhPVI2OCCwTR?= NGjLOmU3NTd{IHi= M4rWO2ROW09? NYHIUG9m[2G3c3XzJIEh\3KnYYTldkBqdmirYnn0c5J6KGWoZnXjeEBkd22kaX7lJJdqfGhiVGjUJI9zKGW{bH;0bY5q[g>? NITpbnczOjl7NEe4NC=>
MG-63 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfUN|AxKG6P M4H4WFEzKGh? NFr3eGZFVVOR NIX2XItqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hQDZn MoDkNlI4QTl|M{i=
MG-63 NXfnSXZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jIWVMxOCCwTR?= MW[yOEBp NYTDcW1rTE2VTx?= NWXkUXRUcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDZ5JR?= MWSyNlc6QTN|OB?=
MG-63 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrjTVg{ODBibl2= M{CzOlQ5KGh? MUHEUXNQ NWnEVZBKcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDV4JR?= NITKeXUzOjd7OUOzPC=>
HL60  M4qxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe5S3VZOTVyLUO1NEBvVQ>? M{PjWFI1KGh? M4O3XIlv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0> M4HZUVIzPzV|N{O5
U937 M1;Bb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[xOVAuOzVyIH7N NIDGRoYzPCCq NF7oWpFqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYRCpJdp\W5iY3;uZ4VvfHKjdHnvcpMhcGmpaHXyJJRp[W5iMkWwJI5O M1jTclIzPzV|N{O5
SCC-6 NFjzVWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXCPG0zODBvM{KwNEBvVQ>? M4ixXVEzNzJ2L{S4JIg> Mo\xSG1UVw>? MlPxbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gc4YhW0OFLU[gZ4VtdHNiaX6gZUBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NXX6dGJ6OjJ3NUKzNlE>
U87  NIf1fnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLzRVAyODBvM{CwJI5o MoO3NlQhcA>? M3nZfolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A4OiViIHH0JFIxOG6p MYeyNlI4ODh2OR?=
K562 M1nZcWZ2dmO2aX;uJGF{e2G7 NYnke3E1OSEQvF2= M1PrUFEzKGh? MU\EUXNQ MnnO[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= NWP2WZdvOjJzN{mxPVg>
Reh MYfGeY5kfGmxbjDBd5NigQ>? NVLr[ZZxOC5|L{Gg{txO Mo\ONVIhcA>? NGnFeFBFVVOR NHmzZ4pmdmijbnPld{B1cGViZYjwdoV{e2mxbjDv[kBTXU6[MzDpcoR2[2WmIHL5JFUu[XqjLVPkVi=> NXrmNG1zOjJzN{mxPVg>

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02959905 Recruiting Metastatic Melanoma BGI, China|Sun Yat-sen University December 2016 Phase 1
NCT02486965 Recruiting Fibromyalgia University Hospital, Brest October 2015 --
NCT01954433 Recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG), Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Unknown status Pain Massachusetts General Hospital June 2012 --
NCT02762903 Completed Osteoarthritis Columbia University August 2009 --
NCT00914173 Completed Pain Medasense Biometrics Ltd November 2008 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID